340B hospitals buy medicines for pennies, then can mark them up by thousands of dollars. This is a hidden tax on patients, employers and taxpayers. It’s time to fix 340B. Read more:

Since 1992, the PDUFA program has been instrumental in making America the best place in the world for R&D and patient access. We’re committed to working with the FDA & other stakeholders to ensure the timely negotiation and reauthorization of PDUFA.

Hospitals are using scare tactics in attempt to block commonsense 340B rebate model pilot. Lawmakers and the administration shouldn’t fall for it. Get the facts: https://t.co/u8iZva9Jqw

NC’s Research Triangle Park is home to hundreds of companies developing next-gen medicines and supporting thousands of skilled workers. This Manufacturing Month, learn more about NC's one-of-a-kind manufacturing and research hub: https://t.co/I5zrajYajA

PBMs and insurers are finally acknowledging what we have known for a long time – patients will benefit directly from sharing discounts, and this does not raise premiums. It’s time for federal oversight and reform to ensure savings reach patients.

.@RobZirk said it best: The US is the global leader in biopharmaceutical innovation because of strategic policy choices. This status is not guaranteed so we must continue to support and incentivize American innovation.

A new study shows a 1,500-case outbreak could cost $90M in one year. Vaccines prevent illness and avoid costs that burden families, health systems and budgets. Read more:

mRNA tech bolsters America's innovation leadership and national security. Without sustained investment and commitment put towards mRNA, the US risks jeopardizing public health preparedness, economic competitiveness and strategic influence. https://t.co/Jh11Dm3xME

.@EliLillyandCo’s plans to build a new manufacturing site in Virginia highlights our industry’s commitment to American-driven innovation. This facility will support local communities and help deliver next-generation medicines. Learn more: https://t.co/qIVA6xMGUj

As a nurse, Sharon has seen both sides: patients battling preventable diseases, and the powerful protection vaccines can provide: https://t.co/i0jCykWx2O

The takeaway is clear: big hospitals are exploiting the 340B program and it is costing patients, taxpayers and employers billions. It’s time to fix 340B.

🏛️Michelle Rosenberg from @USGAO reiterated that there is no requirement for hospitals to use profits from the program to help patients. . The program’s lack of guardrails and transparency is driving up costs for both patients and taxpayers.

📊Testimony from Dr. Aditi Sen of the nonpartisan @USCBO underscored that the 340B program incentivizes practices that drive up costs for taxpayers by billions of dollars each year: https://t.co/LqoboQZtq4

Yesterday’s Senate HELP Committee hearing confirmed what a growing body of evidence has shown: the 340B program is exploited by large hospitals with no evidence that patients are benefiting. The program is a hidden tax on patients, taxpayers and employers. ⬇️

@USCBO @WSJ @Health_Affairs @HealthAffairs The bottom line: The nonpartisan CBO report shows that the 340B program is increasing costs and found no evidence patients are benefitting. So where’s the money going? Today’s hearing made it clear: we need federal action now to fix 340B.

@USCBO @WSJ @Health_Affairs A @HealthAffairs study found that 340B hospitals actually prescribe fewer biosimilars than non-340B hospitals for Medicare patients. This drives up costs for Medicare.

@USCBO @WSJ Senators raised concerns that rural hospitals are not benefitting appropriately the 340B program. As an example, a @Health_Affairs study shows big-city hospitals are posing as “rural” to grab discounts meant for underserved patients:

@USCBO @WSJ The 340B program costs an estimated $20B each year in lost Medicare & Medicaid rebates (source: BRG). That’s a hidden tax on patients, taxpayers, and employers: https://t.co/HfspKprYPo

@USCBO Even @WSJ calls 340B reform “a good idea to cut drug costs,” noting big hospitals have profited at patients' and taxpayers’ expense: https://t.co/plDd5ctWB1

A nonpartisan @USCBO report–mentioned in today’s Senate HELP hearing–confirmed that unchecked 340B growth and abuse drives up costs for taxpayers, without evidence that patients benefit. It’s time for oversight and reform: https://t.co/LqoboQYVAw

There’s growing evidence that large, tax-exempt hospitals are exploiting the 340B program—marking up medicines by 1,000% or more and costing taxpayers billions, with little oversight or proven benefit to patients. Here are the facts👇